-
Sun Yat-sen University Fu Liwu/Huang Qiang reveals the underlying mechanism of this type of lymphoma getting worse after receiving GM-CSF treatment
Time of Update: 2021-06-05
In summary, these findings indicate that GM-CSF may trigger the loss of tumor immune surveillance in ENKTL patients and promote disease progression, which is related to STAT5 mutation and JAK2 hyperphosphorylation, and then up-regulates the expression of PD-L1.
-
Case sharing|Treplimumab combined with chemotherapy has significant benefits in the treatment of esophageal squamous cell carcinoma
Time of Update: 2021-06-05
Figure 7 Comparison of chest enhanced CT results on February 24, 2021 and April 12, 2021 Figure 8 Case analysis of changes in tumor markers The patient was diagnosed as "esophageal squamous cell carcinoma (T4bNxMx IVA stage AJCC 8th stage)", and the first-line treatment is Concurrent radiotherapy and chemotherapy, including 2 cycles of chemotherapy + full course of radiotherapy, the tumor was significantly reduced, and the disease was stable after 4 cycles of chemotherapy.
-
CSCO Immuno-Oncology Summit Forum: Global Voices and Chinese Perspectives in the "Era of Maritime" Immunotherapy
Time of Update: 2021-06-05
Professor Wang Jun from the First Affiliated Hospital of Shandong First Medical University commented on the results of these two important studies and their significance in the "Research Progress in Advanced Thoracic Tumor Combination Therapy" session of the conference satellite conference: Professor Wang Jun's drive For patients with gene-negative advanced NSCLC, the existing first-line immune monotherapy requires precise screening of patients, and achieving "chemotherapy-free" for a wider population is always the direction of our clinical efforts.
-
Journal of Clinical Oncology | China's first anti-tumor treatment-induced acute oral mucositis diagnosis and prevention expert consensus released
Time of Update: 2021-06-05
On May 30, my country’s first "Expert Consensus on the Diagnosis and Prevention of Acute Oral Mucositis Caused by Anti-tumor Therapy" (hereinafter referred to as "OM Consensus") was published in the
-
SCLC patients receive metformin combined with nivolumab, the tumor shrinks significantly?
Time of Update: 2021-06-05
This article reports a case of small cell lung cancer (SCLC) patients who received nivolumab treatment for two years Progress, and then received metformin combined with nivolumab treatment, within six months, the patient's efficacy reached a partial remission (PR).
-
Enter "Under Approval"!
Time of Update: 2021-06-05
Medicine New Observation May 31, 2021/eMedClub News/--China's National Medical Products Administration (NMPA) drug registration progress query results show that Cinda Bio and Eli Lilly and Company collaborated on research and development For the PD-1 inhibitor Sintilimab, the review status of its new indication for marketing application has been updated to: Under approval, which means that this new indication is expected to be approved in the near future.
-
Finally waiting for you, the first KRAS gene targeting drug AMG510 has been approved for marketing
Time of Update: 2021-06-05
CodeBreak 100 clinical trial confirms the efficacy of AMG510 In a Phase II clinical trial of CodeBreak 100, 124 patients with locally advanced or metastatic non-small cell lung cancer with G12C mutations in the KRAS gene were included.
-
Researchers establish a patient typing model based on epigenetic heterogeneity of lung adenocarcinoma
Time of Update: 2021-06-05
In order to explore whether this apparent group-based lung adenocarcinoma typing model can be applied to other patients, the researchers used the respective feature gene sets of the two subgroups to divide the lung adenocarcinoma patients in the TCGA database into G I-like and G II-like two groups, and found that they have significantly different survival times, and G II-like patients generally have a higher tumor mutation burden and more tumor suppressor gene mutations.
-
Self Renew column｜Targeted anti-tumor therapy derived from autoimmune diseases—review a 2016 article
Time of Update: 2021-06-05
If antibodies that target extracellular DNA can be used, we have the hope of achieving precise delivery of anti-tumor drug molecules.
In this way, as the treatment progresses, the antigen at the tumor site not only does not decrease, but increases, so as to maintain or even continuously improve the delivery effect of the drug.
-
ASCO first look | Targeting and immune complement each other, enriching early and mid-term NSCLC treatment options
Time of Update: 2021-06-05
Model QALY Benefits and Costs Invested in Erlotinib (E) Compared with Vinorelbine + Cisplatin (NP) in a Randomized Phase II EVAN Study of Adjuvant Treatment for Chinese Patients with Stage IIIA EGFR-mutant NSCLC, Overall Survival and Exploration The updated results of the sexual analysis: mOS has been improved, and DFS is affected by co-mutation (abstract number: 8520).
-
[One picture, one drug] Janssen Amivantamab was approved for marketing, the world's first bispecific antibody for the treatment of NSCLC
Time of Update: 2021-06-05
The drug was approved by the US FDA on May 21, 2021 for the treatment of non-small cell lung cancer with EGFR mutations [1].
2~3% of patients with non-small cell lung cancer have EGFR exon 20 insertion mutations.
https:// -therapy-subset-non-small-cell-lung-cancer3.
-
How to manage multiple myeloma for a long time?
Time of Update: 2021-06-05
Introduction "Continuous treatment of multiple myeloma" The second article in the series, fixed cycle treatment or continuous treatment, which is more conducive to the long-term management of multipl
-
Finding the weakness of drug-resistant colorectal cancer: WRN gene is expected to become a new target for the treatment of drug-resistant colorectal cancer
Time of Update: 2021-06-05
In general, the authors studied the therapeutic potential of targeting WRN in a preclinical model of dMMR colorectal cancer, and found that more than 90% of the models are dependent on WRN, which supports WRN is used as a target for dMMR/MSI-H tumor monotherapy or combined with targeted drugs, chemotherapy or immunotherapy.
-
3+ meristem letter + clinical liver cancer SCI, hurry up and learn!
Time of Update: 2021-06-05
Click [Medical prescription] Follow our clinical partners to post articles with various difficulties, how to break it? Today, I will interpret the latest article published in Cancer Medicine (IF=3. 4
-
The world's first KRAS inhibitor!
Time of Update: 2021-06-05
S. Food and Drug Administration (FDA) has accelerated the approval of its KRAS G12C inhibitor LUMAKRAS™ (Sotorasib, R&D code AMG 510) for the market, for treatment that has received at least one early stage Systemic treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients with KRAS G12C mutation.
-
The Hope of Lai Su|Professor Bai Yuxian: National medicine shines in ASCO, adding a new weapon in the field of biliary tumors
Time of Update: 2021-06-05
For example, the "cola" combination composed of lenvatinib and pembrolizumab, which is currently used more clinically, is shown according to the data released by 2021ASCO [2], this combination plan is a second-line treatment In patients with advanced (metastatic and/or unresectable) BTC, ORR was 10%, DCR was 68%, median PFS was 6.
-
Receiving ionizing radiation at a young age can cause malignant lymphoma?
Time of Update: 2021-06-05
Indications for adjuvant treatment of icotinib will soon be approved 01Leukemia: Will receiving ionizing radiation at a young age cause malignant lymphoma?
The investigator said: In the trial of stage III breast cancer (neo) adjuvant therapy included in premenopausal women, the effect of drug intervention on ovarian function is rarely evaluated.
-
The first KRAS inhibitor received accelerated FDA approval today to treat non-small cell lung cancer
Time of Update: 2021-06-05
▎The content team editor of WuXi AppTec today, the US Food and Drug Administration announced that it has accelerated the approval of Lumakras (sotorasib) developed by Amgen for the treatment of non-small cell lung cancer (NSCLC) patients whose tumors carry the KRAS G12C mutation.
-
Lucky Anti-cancer: What are the characteristics of those "super responders" whose tumors have completely disappeared?
Time of Update: 2021-06-05
For example, the third super responder, a HER2-positive metastatic breast cancer patient, was treated with trastuzumab, carboplatin, and docetaxel in complete remission lasting for 7 years.
-
Nature Sub-Journal | Chen Jun and other teams from Fudan University develop new nanomaterials to target tumors that have metastasized throughout the body
Time of Update: 2021-06-05
Metastasis involves three steps: (i) tumor cells infiltrate the circulatory system from the primary site through epithelial-mesenchymal transition (EMT), (ii) circulating tumor cells (CTC) and platelets form "microthrombi" to avoid immune surveillance in the circulation , And (iii) CTC is colonized in the niche before the transfer.
